https://www.selleckchem.com/products/mrtx1133.html
DFS in adenocarcinoma patients. These results could be driven by the small number of patients and require validation. A small prognostic effect of KRAS mutation was identified for LCSS, and a trend towards worse LCSS, DFS and OS was noted for KRAS MUT + Gain. A potential predictive effect of concomitant KRAS mutation and copy number gain was observed for DFS in adenocarcinoma patients. These results could be driven by the small number of patients and require validation. The current National Comprehensive Cancer Network (NCCN) guideline
Like
Comment
Share
